2022 World Conference on Lung Cancer (ePosters)-EP02.01-013. Real World Treatment Patterns, Prevalence and Outcomes in Patients with KRAS Mutated Non Small Cell Lung Cancer in Southwestern Ontario

EP02.01-013. Real World Treatment Patterns, Prevalence and Outcomes in Patients with KRAS Mutated Non Small Cell Lung Cancer in Southwestern Ontario

Back to course

Pdf Summary

This document discusses the treatment patterns, prevalence, and outcomes of patients with KRAS mutated non-small cell lung cancer (NSCLC) in Southwestern Ontario. KRAS mutations occur in 20-40% of lung adenocarcinomas, and the most common subtypes include G12C, G12V, and G12D. Previous studies have suggested that KRAS mutations are associated with worse overall survival in patients with NSCLC. However, this study found that in the context of resected stage I-III NSCLC, patients with KRAS mutations demonstrated lower recurrence rates compared to those without KRAS mutations. The difference in recurrence rates was statistically significant. Although recurrence-free survival was greater for patients with KRAS mutations, it was not statistically significant after adjusting for stage. The study also observed lower rates of distant metastasis and central nervous system involvement as the first site of distant metastases in patients with KRAS mutations, although these differences were not statistically significant. Overall survival did not significantly differ between patients with KRAS mutations and those without. The study suggests that these findings warrant further evaluation with larger cohorts of patients to determine the prognostic role of KRAS mutations in the context of resected stage I-III NSCLC. Additionally, the study suggests that this information may provide context for emerging clinical trials exploring novel targeted therapies for this patient population.

Asset Subtitle

Sara Kuruvilla

Meta Tag

Speaker Sara Kuruvilla

Topic Early Stage Non-small Cell Lung Cancer - Biomarkers

Keywords

KRAS mutated non-small cell lung cancer

NSCLC

Southwestern Ontario

KRAS mutations

lung adenocarcinomas

recurrence rates

resected stage I-III NSCLC

overall survival

distant metastasis

prognostic role